Early Cancer Screening’s Cost Effectiveness Checked

Cost-effectiveness of early cancer screening in Li-Fraumeni syndrome patients is being checked here in this study.

Cost Effectiveness Of Early Cancer Screening programme In a genetic disorder like Li-Fraumeni Syndrome is being Checked for in this study. They have mostly focused on patients who have a high risk of developing cancer.

New research published today in the journal Pediatric Blood and Cancer shows how early cancer screening and surveillance in patients with Li-Fraumeni Syndrome (LFS) results in additional years of life, and is cost effective for third-party payers.

Early Cancer Detection Could Be Done With A Blood Test
Lymphocyte Genome Sensitivity(LGS) test, is the newest blood test test developed by researchers to detect cancer in its early stages.

‘It has been found that LFS patients who received early cancer surveillance extended their lifetime, but had to endure higher healthcare costs. With each additional year of life, these patients gained, payers had an incremental medical cost of about $17,000.’

LFS is an inherited genetic condition that greatly increases the risk of developing several types of cancer. People diagnosed with LFS have a one in two chance of developing cancer by 30, and a nearly 100 percent risk of developing cancer in their lifetime, compared to the lifetime cancer risk of the average person of almost 40 percent.

The study, led by Joshua Schiffman, MD, cancer researcher at Huntsman Cancer Institute (HCI) and professor of pediatrics at the University of Utah (U of U), in collaboration with Casey Tak, PhD, assistant professor at the University of North Carolina Eshelman School of Pharmacy, looked at data throughout the lifetimes of patients who were diagnosed with LFS. The researchers examined the cumulative costs and life expectancy for these high-risk patients, comparing those who received cancer surveillance with those who did not.

"We were able to simulate the costs and benefits of early cancer surveillance versus standard of care over a lifetime," said Schiffman. "This allowed us to gain a long-term view of the effects that undergoing, or not undergoing; cancer surveillance may have for patients with LFS."

Blood Test for Early Cancer Detection
Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center researchers have developed a simple and easy blood test to provide early detection of many types of cancer.

By using a decision-analytical model, the researchers showed that LFS patients who received early cancer surveillance extended their lifetime, but incurred higher healthcare costs. With each additional year of life, these patients gained, payers had an incremental medical cost of about $17,000. This expenditure compares very favorably to commonly accepted thresholds of willingness to pay per life-year gained of $100,000.

"This type of research has been conducted in other populations who are at high risk of cancer development, and it is nice to see this also holds true for patients with LFS," said Schiffman. "One of the biggest clinical challenges we have with early cancer screenings for our LFS patients is receiving insurance approval. Hopefully, we can use this research to show that, not only does early cancer screening save lives, but it is also cost effective for LFS patients."

Artificial Intelligence Research for Early Cancer Diagnosis
British Prime Minister Theresa May promises funding for AI-based research to improve cancer diagnosis.

The research team plans to continue to investigate and validate the cost-effectiveness of early tumor surveillance for patients with LFS, including determining the actual number of dollars spent with various healthcare systems.

"Ensuring patients with LFS have good and affordable access to cancer surveillance will result in more cost-effective care for the entire healthcare system," said Tak.

Cyprus University Researchers Design Early Cancer Screening Device
The capsule is designed to detect micro-cancers in the small intestine, thus enabling early detection and removal of cancerous cells.

Source-Eurekalert